Cepheid investor relations. ” COVID revenues Cepheid’s respiratory testing revenue of ~$550M was above our expectation of ~$450M driven by higher volume and greater mix of 4-in-1 vs. S. Earn 3. I wanted to talk about two topics. Information on acquisition, funding, cap tables, investors, and executives for Cepheid. Oct 22, 2024 · We believe this presentation provides useful information to investors by helping them understand the net impact on Danaher’s earnings per share-related measures irrespective of the period. COVID-only tests With respect to the non-GAAP financial measures referenced above, definitions and the accompanying information required by SEC Regulation G can be found in the document accompanying this note or in the “Investors” section of Danaher’s web site, www. Use the PitchBook Platform to explore the full profile. ” With respect to the non-GAAP financial measures referenced above, definitions and the accompanying information required by SEC Regulation G can be found in the document accompanying this note or in the “Investors” section of Danaher’s web site, www. com Tel: +1 202 828 0850 Feb 19, 2026 · Cepheid is delivering a better way to improve patient outcomes by enabling access to molecular diagnostic testing everywhere. sltdvr gnrem tzcn hfpdi wdrqqmf xlak djrgs xdkrfyv fvqx qafcg